The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.

Sanofi (NYSE: SNY) acquired the Framingham facility when it bought Massachusetts-based Genzyme in a deal worth over $20 billion in 2011. Genzyme became a subsidiary of Sanofi and kept the Genzyme ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.

Jan. 23—THURSDAY, Jan. 23, 2025 (HealthDay News) — The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current Good ...

THURSDAY, Jan. 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about ... plant in Framingham, Massachusetts. On Jan. 15, 2025 ...

The Food and Drug Administration has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility in Massachusetts where the company makes ...

The latest cuts from the Waltham-based company come just a few months after Thermo Fisher (NYSE: TMO) disclosed layoffs impacting a total of 160 employees across three sites. Thermo Fisher notified ...

THURSDAY, Jan. 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant ... at their Genzyme manufacturing plant in Framingham, ...

(HealthDay News) — The US Food and Drug Administration (FDA) has warned Sanofi about significant ... their Genzyme manufacturing plant in Framingham, Massachusetts. On January 15, a warning ...